Cerecor to Present at Upcoming Investor Conferences
September 10 2020 - 7:00AM
Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on
becoming a leader in development and commercialization of
treatments for rare and orphan diseases, today announced that
Michael F. Cola, President and Chief Executive Officer, will
present at two upcoming virtual conferences.
H.C. Wainwright 22nd Annual Global Investment
ConferenceDate: Monday, September 14, 2020Time: 3:00 PM ET
Oppenheimer Fall Healthcare Life Sciences & MedTech
SummitDate: Monday, September 21, 2020Time: 1:40 PM ET
A live webcast of the presentations can be accessed under
"News/Events" page in the Investors section of the Company's
website at www.cerecor.com.
About Cerecor
Cerecor is a biopharmaceutical company focused on becoming a
leader in development and commercialization of treatments for rare
and orphan diseases. The company is advancing its clinical-stage
pipeline of innovative therapies that address unmet patient needs
within rare and orphan diseases. The company's rare disease
pipeline includes CERC-801, CERC-802 and CERC-803 ("CERC-800
compounds"), which are therapies for inherited metabolic disorders
known as congenital disorders of glycosylation. The U.S. Food and
Drug Administration ("FDA") granted Rare Pediatric Disease
Designation (“RPDD”) and Orphan Drug Designation ("ODD") to all
three CERC-800 compounds, thus potentially qualifying the Company
to receive a Priority Review Voucher ("PRV") upon approval of each
new drug application ("NDA"). The company is also developing
CERC-002, CERC-006 and CERC-007. CERC-002 is an anti-LIGHT
monoclonal antibody being developed for the treatment of severe
pediatric-onset Crohn's disease, and is also in a clinical trial
for COVID-19 acute respiratory distress syndrome. CERC-006 is a
dual mTOR inhibitor being developed for the treatment of complex
lymphatic malformations and has been granted RPDD and ODD by the
FDA, thus potentially qualifying the company to receive a fourth
PRV upon approval of an NDA. CERC-007 is an anti-IL-18 monoclonal
antibody being developed for the treatment of autoimmune
inflammatory diseases such as adult onset Stills disease, and
multiple myeloma.
For more information about Cerecor, please visit
www.cerecor.com.
Forward-Looking StatementsThis press release
may include forward-looking statements made pursuant to the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements are statements that are not historical facts. Such
forward-looking statements are subject to significant risks and
uncertainties that are subject to change based on various factors
(many of which are beyond Cerecor’s control), which could cause
actual results to differ from the forward-looking statements. Such
statements may include, without limitation, statements with respect
to Cerecor’s plans, objectives, projections, expectations and
intentions and other statements identified by words such as
“projects,” “may,” “might,” “will,” “could,” “would,” “should,”
“continue,” “seeks,” “aims,” “predicts,” “believes,” “expects,”
“anticipates,” “estimates,” “intends,” “plans,” “potential,” or
similar expressions (including their use in the negative), or by
discussions of future matters such as: the development of product
candidates or products; timing and success of trial results and
regulatory review; potential attributes and benefits of product
candidates; and other statements that are not historical. These
statements are based upon the current beliefs and expectations of
Cerecor’s management but are subject to significant risks and
uncertainties, including: drug development costs, timing and other
risks, including reliance on investigators and enrollment of
patients in clinical trials, which might be slowed by the COVID-19
pandemic; regulatory risks; Cerecor's cash position and the
potential need for it to raise additional capital; general economic
and market risks and uncertainties, including those caused by the
COVID-19 pandemic; and those other risks detailed in Cerecor’s
filings with the Securities and Exchange Commission. Actual results
may differ from those set forth in the forward-looking statements.
Except as required by applicable law, Cerecor expressly disclaims
any obligations or undertaking to release publicly any updates or
revisions to any forward-looking statements contained herein to
reflect any change in Cerecor’s expectations with respect thereto
or any change in events, conditions or circumstances on which any
statement is based.
For media and investor inquiries
James HarrellInvestor RelationsChief Commercial OfficerCerecor
Inc.jharrell@cerecor.com623.439.2220 office
Cerecor (NASDAQ:CERC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cerecor (NASDAQ:CERC)
Historical Stock Chart
From Sep 2023 to Sep 2024